Table 1.
Characteristics of 283 perinatally HIV-1-infected children and adolescents studied
| Total | Female | Male | |
|---|---|---|---|
| Characteristics | n=283 | n=142 | n=141 |
| Median age, years (IQR) | 10 (8 to 13) | 10 (8 to 13) | 10 (8 to 13) |
| Age categories, n (%) | |||
| <5 yearsa | 20 (7.1%) | 7 (4.9%) | 13 (9.2%) |
| 5 to 10 years | 127 (44.9%) | 69 (48.6%) | 58 (41.1%) |
| 11 to 14 years | 98 (34.6%) | 50 (35.2%) | 48 (34.1%) |
| 15 to 19 years | 38 (13.4%) | 16 (11.3%) | 22 (15.6%) |
| Orphaned, n (%) | |||
| No | 96 (33.9%) | 49 (34.5%) | 47 (33.3%) |
| Yes | 89 (31.4%) | 49 (34.5%) | 40 (28.4%) |
| Unknown | 98 (34.6%) | 44 (31.0%) | 54 (38.3%) |
| Geographical area, n (%) | |||
| Urban (Lomé, capital city) | 189 (66.8%) | 90 (63.4%) | 99 (70.2%) |
| Semi-rural | 94 (33.2%) | 52 (36.6%) | 42 (29.8%) |
| Months on ART, median (IQR) | 48 (28 to 68) | 44 (27 to 65) | 52 (30 to 70) |
| Months on ART per age category, median (IQR) | |||
| <5 years | 21 (15 to 27) | 20 (15 to 29) | 21 (14 to 27) |
| 5 to 10 years | 41 (27 to 57) | 44 (28 to 60) | 48 (27 to 63) |
| 11 to 14 years | 57 (33 to 76) | 48 (31 to 76) | 53 (36 to 76) |
| 15 to 19 years | 64 (52 to 86) | 62 (39 to 84) | 72 (58 to 98) |
| Months on ART per geographical area, median (IQR) | |||
| Urban, Lomé, capital city | 50 (30 to 73) | 41 (27 to 62) | 55 (36 to 76) |
| Semi-rural | 46 (26 to 68) | 45 (27 to 68) | 46 (26 to 60) |
| ART regimen at inclusion, n (%) | |||
| AZT+3TC+NVP/EFV | 228 (80.6%) | 119 (83.8%) | 109 (77.3%) |
| ABC+3TC+NVP/EFV | 16 (5.7%) | 8 (5.7%) | 8 (5.7%) |
| TDF+3TC+EFV | 8 (2.8%) | 4 (2.8%) | 4 (2.8%) |
| AZT+3TC+ABC/TDF | 3 (1.0%) | 1 (0.7%) | 2 (1.4%) |
| ABC+3TC+LPV/r or ATV/r | 16 (5.7%) | 4 (2.8%) | 12 (8.5%) |
| AZT+3TC+LPV/r | 7 (2.5%) | 4 (2.8%) | 3 (2.1%) |
| TDF+3TC+LPV/r or ATV/r | 5 (1.7%) | 2 (1.4%) | 3 (2.1%) |
| Previous changes in ART regimen, n (%) | |||
| No | 138 (48.8%) | 74 (52.1%) | 64 (45.4%) |
| Yes | 135 (47.7%) | 63 (44.4%) | 72 (51.1%) |
| Not available | 10 (3.5%) | 5 (3.5%) | 5 (3.5%) |
| CD4 counts | |||
| Available at sampling time, n (%) | 163 (57.6%) | 86 (60.6%) | 77 (54.6%) |
| Median cell counts, cells/mm3 (IQR) | 610 (347 to 947) | 670 (302 to 905) | 610 (412 to 1023) |
| PMTCT exposure, n (%) | |||
| Yes | 10 (3.5%) | 3 (2.0%) | 7 (5.0%) |
| No | 165 (58.3%) | 81 (57.0%) | 84 (59.6%) |
| Not available | 108 (38.2%) | 58 (41.0%) | 50 (35.4%) |
| Breastfeeding at a young age, n (%) | |||
| Yes | 159 (56.2%) | 77 (54.2%) | 82 (58.5%) |
| No | 1 (0.3%) | 1 (0.7%) | 0 (0.0%) |
| Not available | 123 (43.5%) | 65 (45.1%) | 58 (41.5%) |
IQR, interquartile ratio; ART, antiretroviral therapy; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; ABC, abacavir; TDF, tenofovir; LPV/r, boosted lopinavir; ATV/r, boosted atazanavir; PMTCT, prevention of mother-to-child transmission.
a
Only two children were less than three years old.